Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 123

1.

Side-effects profile and outcomes of ponatinib in the treatment of chronic myeloid leukemia.

Chan O, Talati C, Isenalumhe L, Shams S, Nodzon L, Fradley M, Sweet K, Pinilla-Ibarz J.

Blood Adv. 2020 Feb 11;4(3):530-538. doi: 10.1182/bloodadvances.2019000268.

2.

Decoding Bone Marrow Fibrosis in Myelodysplastic Syndromes.

Melody M, Al Ali N, Zhang L, Ramadan H, Padron E, Sallman D, Sweet K, Lancet J, List A, Bennett JM, Komrokji R.

Clin Lymphoma Myeloma Leuk. 2020 Jan 14. pii: S2152-2650(20)30039-2. doi: 10.1016/j.clml.2020.01.003. [Epub ahead of print]

PMID:
32044274
3.

Blastic plasmacytoid dendritic cell neoplasm: diagnosis, manifestations, and treatment.

Sweet K.

Curr Opin Hematol. 2020 Mar;27(2):103-107. doi: 10.1097/MOH.0000000000000569.

PMID:
31972688
4.

Prevalence, incidence, and distribution of human papillomavirus types in female sex workers in Kenya.

Sweet K, Bosire C, Sanusi B, Sherrod CJ, Kwatampora J, Waweru W, Mugo N, Kimani J, Ting J, Clark J, Dittmer DP, Smith JS.

Int J STD AIDS. 2020 Feb;31(2):109-118. doi: 10.1177/0956462419884454. Epub 2020 Jan 16. No abstract available.

PMID:
31948341
5.

Generation of Antitumor T Cells For Adoptive Cell Therapy With Artificial Antigen Presenting Cells.

Shrestha B, Zhang Y, Yu B, Li G, Boucher JC, Beatty NJ, Tsai HC, Wang X, Mishra A, Sweet K, Lancet JE, Kelley L, Davila ML.

J Immunother. 2019 Dec 4. doi: 10.1097/CJI.0000000000000306. [Epub ahead of print]

PMID:
31834208
6.

Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia.

Sweet K, Komrokji R, Padron E, Cubitt CL, Turner JG, Zhou J, List AF, Sallman DA, Dawson JL, Sullivan DM, Chavez J, Shah BD, Lancet JE.

Clin Cancer Res. 2020 Jan 1;26(1):54-60. doi: 10.1158/1078-0432.CCR-19-2169. Epub 2019 Oct 21.

PMID:
31636097
7.

Internet-assisted cognitive behavioral intervention for targeted therapy-related fatigue in chronic myeloid leukemia: Results from a pilot randomized trial.

Jim HSL, Hyland KA, Nelson AM, Pinilla-Ibarz J, Sweet K, Gielissen M, Bulls H, Hoogland AI, Jacobsen PB, Knoop H.

Cancer. 2020 Jan 1;126(1):174-180. doi: 10.1002/cncr.32521. Epub 2019 Sep 25.

PMID:
31553815
8.

Snap shot: Achieving better care through a one-page personal health profile.

Aston M, Sweet K, McAfee E, Price S, Sheriko J, Monaghan J, Filliter J, Walls C, McGrath P, Vanderlee E, Bye A.

J Intellect Disabil. 2019 Sep 22:1744629519873503. doi: 10.1177/1744629519873503. [Epub ahead of print]

PMID:
31544589
9.

Driver mutation-specific clinical and genomic correlates differ between primary and secondary myelofibrosis.

Kuykendall AT, Talati C, Padron E, Sweet K, Lancet JE, List AF, Sallman D, Komrokji RS.

Am J Hematol. 2019 Dec;94(12):E314-E317. doi: 10.1002/ajh.25625. Epub 2019 Sep 10. No abstract available.

PMID:
31444809
10.

Prognostic significance of MYC oncoprotein expression on survival outcome in patients with acute myeloid leukemia with myelodysplasia related changes (AML-MRC).

Yun S, Sharma R, Chan O, Vincelette ND, Sallman DA, Sweet K, Padron E, Komrokji R, Lancet JE, Abraham I, Moscinski LC, Cleveland JL, List AF, Zhang L.

Leuk Res. 2019 Sep;84:106194. doi: 10.1016/j.leukres.2019.106194. Epub 2019 Jul 18.

PMID:
31357093
11.

Data on SVCT2 transporter expression and localization in cancer cell lines and tissues.

Roa FJ, Peña E, Inostroza E, Sotomayor K, González M, Gutierrez-Castro FA, Maurin M, Sweet K, Labrousse C, Gatica M, Aylwin CF, Mendoza P, Maldonado M, Delgado C, Madariaga J, Panes J, Silva-Grecchi T, Concha II, Moraga-Cid G, Reyes AM, Muñoz-Montesino C, Vera JC, Rivas CI.

Data Brief. 2019 May 6;25:103972. doi: 10.1016/j.dib.2019.103972. eCollection 2019 Aug.

12.

Comparisons of commonly used front-line regimens on survival outcomes in patients aged 70 years and older with acute myeloid leukemia.

Talati C, Dhulipala VC, Extermann MT, Ali NA, Kim J, Komrokji R, Sweet K, Kuykendall A, Sehovic M, Reljic T, Djulbegovic B, Lancet JE.

Haematologica. 2020 Jan 31;105(2):398-406. doi: 10.3324/haematol.2018.208637. Print 2020.

13.

Responsiveness of Serum C-Reactive Protein, Interleukin-17A, and Interleukin-17F Levels to Ustekinumab in Psoriatic Arthritis: Lessons From Two Phase III, Multicenter, Double-Blind, Placebo-Controlled Trials.

Siebert S, Sweet K, Dasgupta B, Campbell K, McInnes IB, Loza MJ.

Arthritis Rheumatol. 2019 Oct;71(10):1660-1669. doi: 10.1002/art.40921. Epub 2019 Sep 3.

PMID:
31070869
14.

A phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS).

Sallman DA, Komrokji RS, Sweet KL, Mo Q, McGraw KL, Duong VH, Zhang L, Nardelli LA, Padron E, List AF, Lancet JE.

Leuk Res. 2019 Jun;81:56-61. doi: 10.1016/j.leukres.2019.03.008. Epub 2019 Mar 30.

PMID:
31030089
15.

Sirukumab and adalimumab reduce power Doppler ultrasound signal in patients with rheumatoid arthritis by 4 weeks in a phase III trial.

Sweet K, Dasgupta B, de Vries D, Gourley I, Hsu B, Loza MJ, Taylor PC.

Ann Rheum Dis. 2019 Oct;78(10):1439-1441. doi: 10.1136/annrheumdis-2019-215183. Epub 2019 Apr 24. No abstract available.

PMID:
31018960
16.

Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm.

Pemmaraju N, Lane AA, Sweet KL, Stein AS, Vasu S, Blum W, Rizzieri DA, Wang ES, Duvic M, Sloan JM, Spence S, Shemesh S, Brooks CL, Balser J, Bergstein I, Lancet JE, Kantarjian HM, Konopleva M.

N Engl J Med. 2019 Apr 25;380(17):1628-1637. doi: 10.1056/NEJMoa1815105.

PMID:
31018069
17.

Stereotactic radiation therapy for canine multilobular osteochondrosarcoma: Eight cases.

Sweet KA, Nolan MW, Yoshikawa H, Gieger TL.

Vet Comp Oncol. 2020 Mar;18(1):76-83. doi: 10.1111/vco.12481. Epub 2019 Jun 17.

PMID:
30989784
18.

Increased expression of mitochondrial sodium-coupled ascorbic acid transporter-2 (mitSVCT2) as a central feature in breast cancer.

Peña E, Roa FJ, Inostroza E, Sotomayor K, González M, Gutierrez-Castro FA, Maurin M, Sweet K, Labrousse C, Gatica M, Aylwin CF, Mendoza P, Maldonado M, Delgado C, Madariaga J, Panes J, Silva-Grecchi T, Concha II, Moraga-Cid G, Reyes AM, Muñoz-Montesino C, Vera JC, Rivas CI.

Free Radic Biol Med. 2019 May 1;135:283-292. doi: 10.1016/j.freeradbiomed.2019.03.015. Epub 2019 Mar 19.

PMID:
30902760
19.

Can increased immunogenicity in chronic myeloid leukemia improve outcomes?

Chan O, Talati C, Sweet K, Pinilla-Ibarz J.

Expert Rev Hematol. 2019 Apr;12(4):225-233. doi: 10.1080/17474086.2019.1588105. Epub 2019 Mar 11.

PMID:
30855193
20.

Mutational Signature Analysis Reveals NTHL1 Deficiency to Cause a Multi-tumor Phenotype.

Grolleman JE, de Voer RM, Elsayed FA, Nielsen M, Weren RDA, Palles C, Ligtenberg MJL, Vos JR, Ten Broeke SW, de Miranda NFCC, Kuiper RA, Kamping EJ, Jansen EAM, Vink-Börger ME, Popp I, Lang A, Spier I, Hüneburg R, James PA, Li N, Staninova M, Lindsay H, Cockburn D, Spasic-Boskovic O, Clendenning M, Sweet K, Capellá G, Sjursen W, Høberg-Vetti H, Jongmans MC, Neveling K, Geurts van Kessel A, Morreau H, Hes FJ, Sijmons RH, Schackert HK, Ruiz-Ponte C, Dymerska D, Lubinski J, Rivera B, Foulkes WD, Tomlinson IP, Valle L, Buchanan DD, Kenwrick S, Adlard J, Dimovski AJ, Campbell IG, Aretz S, Schindler D, van Wezel T, Hoogerbrugge N, Kuiper RP.

Cancer Cell. 2019 Feb 11;35(2):256-266.e5. doi: 10.1016/j.ccell.2018.12.011.

21.

Initial Diagnostic Work-Up of Acute Leukemia: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists and American Society of Hematology Guideline.

de Haas V, Ismaila N, Advani A, Arber DA, Dabney RS, Patel-Donelly D, Kitlas E, Pieters R, Pui CH, Sweet K, Zhang L.

J Clin Oncol. 2019 Jan 20;37(3):239-253. doi: 10.1200/JCO.18.01468. Epub 2018 Dec 3. Erratum in: J Clin Oncol. 2019 Mar 1;37(7):612.

22.

How Online Family History Tool Design and Message Content Impact User Perceptions: An Examination of Family HealthLink.

Thomas SN, Hovick SR, Tan N, Sturm AC, Sweet K.

Public Health Genomics. 2018;21(1-2):53-66. doi: 10.1159/000493847. Epub 2018 Dec 12.

PMID:
30540989
23.

Predictors of risk-reducing surgery intentions following genetic counseling for hereditary breast and ovarian cancer.

Ladd MK, Peshkin BN, Senter L, Baldinger S, Isaacs C, Segal H, Philip S, Phillips C, Shane K, Martin A, Weinstein V, Pilarski R, Jeter J, Sweet K, Hatten B, Wurtmann EJ, Phippen S, Bro D, Schwartz MD.

Transl Behav Med. 2018 Nov 10. doi: 10.1093/tbm/iby101. [Epub ahead of print]

PMID:
30418620
24.

Nuclear transport inhibition in acute myeloid leukemia: recent advances and future perspectives.

Talati C, Sweet KL.

Int J Hematol Oncol. 2018 Sep 11;7(3):IJH04. doi: 10.2217/ijh-2018-0001. eCollection 2018 Oct. Review.

25.

Efficient UV Filter Solubilizers Prevent Recrystallization Favoring Accurate and Safe Sun Protection.

da Silva Souza ID, Berkowitz E, Chea JD, McBride N, Sweet K, Torri D, Burgo RV, Savelski MJ, Stanzione JF 3rd.

ACS Appl Mater Interfaces. 2018 Nov 28;10(47):40411-40423. doi: 10.1021/acsami.8b14204. Epub 2018 Nov 13.

PMID:
30395433
26.

Genetically inspired prognostic scoring system (GIPSS) outperforms dynamic international prognostic scoring system (DIPSS) in myelofibrosis patients.

Kuykendall AT, Talati C, Padron E, Sweet K, Sallman D, List AF, Lancet JE, Komrokji RS.

Am J Hematol. 2019 Jan;94(1):87-92. doi: 10.1002/ajh.25335. Epub 2018 Nov 25.

27.

A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease.

Sweet K, Hazlehurst L, Sahakian E, Powers J, Nodzon L, Kayali F, Hyland K, Nelson A, Pinilla-Ibarz J.

Leuk Res. 2018 Nov;74:89-96. doi: 10.1016/j.leukres.2018.10.002. Epub 2018 Oct 9.

PMID:
30340199
28.

Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis.

Deodhar A, Gensler LS, Sieper J, Clark M, Calderon C, Wang Y, Zhou Y, Leu JH, Campbell K, Sweet K, Harrison DD, Hsia EC, van der Heijde D.

Arthritis Rheumatol. 2019 Feb;71(2):258-270. doi: 10.1002/art.40728. Epub 2018 Dec 29.

29.

Recently approved therapies in acute myeloid leukemia: A complex treatment landscape.

Talati C, Sweet K.

Leuk Res. 2018 Oct;73:58-66. doi: 10.1016/j.leukres.2018.09.001. Epub 2018 Sep 8. Review.

30.

Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology.

Radich JP, Deininger M, Abboud CN, Altman JK, Berman E, Bhatia R, Bhatnagar B, Curtin P, DeAngelo DJ, Gotlib J, Hobbs G, Jagasia M, Kantarjian HM, Maness L, Metheny L, Moore JO, Pallera A, Pancari P, Patnaik M, Purev E, Rose MG, Shah NP, Smith BD, Snyder DS, Sweet KL, Talpaz M, Thompson J, Yang DT, Gregory KM, Sundar H.

J Natl Compr Canc Netw. 2018 Sep;16(9):1108-1135. doi: 10.6004/jnccn.2018.0071.

PMID:
30181422
31.

Early Outcome Data Assessing Utility of a Post-Test Genomic Counseling Framework for the Scalable Delivery of Precision Health.

Sturm AC, Schmidlen T, Scheinfeldt L, Hovick S, McElroy JP, Toland AE, Roberts JS, Sweet K.

J Pers Med. 2018 Jul 25;8(3). pii: E25. doi: 10.3390/jpm8030025.

32.

HIV and viral hepatitis coinfection analysis using surveillance data from 15 US states and two cities.

Bosh KA, Coyle JR, Hansen V, Kim EM, Speers S, Comer M, Maddox LM, Khuwaja S, Zhou W, Jatta A, Mayer R, Brantley AD, Muriithi NW, Bhattacharjee R, Flynn C, Bouton L, John B, Keusch J, Barber CA, Sweet K, Ramaswamy C, Westheimer EF, VanderBusch L, Nishimura A, Vu A, Hoffman-Arriaga L, Rowlinson E, Carter AO, Yerkes LE, Li W, Reuer JR, Stockman LJ, Tang T, Brooks JT, Teshale EH, Hall HI.

Epidemiol Infect. 2018 May;146(7):920-930. doi: 10.1017/S0950268818000766. Epub 2018 Apr 11.

33.

Operationalizing the Reciprocal Engagement Model of Genetic Counseling Practice: a Framework for the Scalable Delivery of Genomic Counseling and Testing.

Schmidlen T, Sturm AC, Hovick S, Scheinfeldt L, Scott Roberts J, Morr L, McElroy J, Toland AE, Christman M, O'Daniel JM, Gordon ES, Bernhardt BA, Ormond KE, Sweet K.

J Genet Couns. 2018 Sep;27(5):1111-1129. doi: 10.1007/s10897-018-0230-z. Epub 2018 Feb 19.

34.

Frequency of an accessory popliteal efferent lymphatic pathway in dogs.

Mayer MN, Sweet KA, Patsikas MN, Sukut SL, Waldner CL.

Vet Radiol Ultrasound. 2018 May;59(3):365-373. doi: 10.1111/vru.12600. Epub 2018 Feb 6.

PMID:
29409165
35.

Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation.

Kuykendall AT, Shah S, Talati C, Al Ali N, Sweet K, Padron E, Sallman DA, Lancet JE, List AF, Zuckerman KS, Komrokji RS.

Ann Hematol. 2018 Mar;97(3):435-441. doi: 10.1007/s00277-017-3194-4. Epub 2017 Nov 30.

PMID:
29189896
36.

Clinical pharmacogenomics: patient perspectives of pharmacogenomic testing and the incidence of actionable test results in a chronic disease cohort.

Mukherjee C, Sweet KM, Luzum JA, Abdel-Rasoul M, Christman MF, Kitzmiller JP.

Per Med. 2017 Sep;14(5):383-388. doi: 10.2217/pme-2017-0022. Epub 2017 Sep 1.

37.

State of the Art Update and Next Questions: Acute Myeloid Leukemia.

Sweet K, Lancet J.

Clin Lymphoma Myeloma Leuk. 2017 Nov;17(11):703-709. doi: 10.1016/j.clml.2017.10.005. Epub 2017 Oct 19. Review.

PMID:
29110833
38.

Comparison of Hallux Rigidus Surgical Treatment Outcomes Between Active Duty and Non-Active Duty Populations A Retrospective Review.

Jones MD, Sweet KJ.

J Am Podiatr Med Assoc. 2018 Jul;108(4):272-279. doi: 10.7547/17-037. Epub 2017 Oct 27.

PMID:
29073775
39.

A Phase II Study of CLAG Regimen Combined With Imatinib Mesylate for Relapsed or Refractory Acute Myeloid Leukemia.

Mirza AS, Lancet JE, Sweet K, Padron E, Pinilla-Ibarz J, Nardelli L, Cubitt C, List AF, Komrokji RS.

Clin Lymphoma Myeloma Leuk. 2017 Dec;17(12):902-907. doi: 10.1016/j.clml.2017.09.007. Epub 2017 Sep 19.

PMID:
29030092
40.

The Treatment Landscape of Myelofibrosis Before and After Ruxolitinib Approval.

Kuykendall AT, Talati C, Al Ali N, Sweet K, Padron E, Sallman DA, Lancet JE, List AF, Zuckerman KS, Komrokji RS.

Clin Lymphoma Myeloma Leuk. 2017 Dec;17(12):e45-e53. doi: 10.1016/j.clml.2017.08.002. Epub 2017 Aug 5.

PMID:
28869184
41.

Stomatal heterogeneity in responses to humidity and temperature: Testing a mechanistic model.

Sweet KJ, Peak D, Mott KA.

Plant Cell Environ. 2017 Nov;40(11):2771-2779. doi: 10.1111/pce.13051.

PMID:
28777880
42.

Cerebral palsy and seizures in a child with tubulinopathy pattern dysgenesis and focal cortical dysplasia.

Sweet KM, Shaw DWW, Chapman T.

Radiol Case Rep. 2017 Jan 30;12(2):396-400. doi: 10.1016/j.radcr.2016.12.008. eCollection 2017 Jun.

43.

Sustained blockade of ascorbic acid transport associated with marked SVCT1 loss in rat hepatocytes containing increased ascorbic acid levels after partial hepatectomy.

Maldonado M, Inostroza E, Peña E, Moncada N, Mardones L, Medina JL, Muñoz A, Gatica M, Villagrán M, Escobar E, Mendoza P, Roa FJ, González M, Guzmán P, Gutiérrez-Castro FA, Sweet K, Muñoz-Montesino C, Vera JC, Rivas CI.

Free Radic Biol Med. 2017 Jul;108:655-667. doi: 10.1016/j.freeradbiomed.2017.04.006. Epub 2017 Apr 15.

PMID:
28419867
44.

Outcomes of a Randomized Controlled Trial of Genomic Counseling for Patients Receiving Personalized and Actionable Complex Disease Reports.

Sweet K, Sturm AC, Schmidlen T, McElroy J, Scheinfeldt L, Manickam K, Gordon ES, Hovick S, Scott Roberts J, Toland AE, Christman M.

J Genet Couns. 2017 Oct;26(5):980-998. doi: 10.1007/s10897-017-0073-z. Epub 2017 Mar 27.

45.

CYP2D6 Genetic Variation and Beta-Blocker Maintenance Dose in Patients with Heart Failure.

Luzum JA, Sweet KM, Binkley PF, Schmidlen TJ, Jarvis JP, Christman MF, Sadee W, Kitzmiller JP.

Pharm Res. 2017 Aug;34(8):1615-1625. doi: 10.1007/s11095-017-2104-8. Epub 2017 Feb 8.

46.

Bone marrow cellularity at day 14 is the most important predictive factor for response in patients with AML who require double-induction chemotherapy: Analysis from a large, single institution experience.

Griffin PT, Komrokji RS, Sweet K, Al Ali NH, Padron E, Kubal TE, List AF, Lancet JE.

Am J Hematol. 2017 Mar;92(3):232-237. doi: 10.1002/ajh.24627. Epub 2017 Feb 3.

47.

NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1.2017.

Pallera A, Altman JK, Berman E, Abboud CN, Bhatnagar B, Curtin P, DeAngelo DJ, Gotlib J, Hagelstrom RT, Hobbs G, Jagasia M, Kantarjian HM, Kropf P, Metheny L, Moore JO, Ontiveros E, Purev E, Quiery A, Reddy VV, Rose MG, Shah NP, Smith BD, Snyder DS, Sweet KL, Tibes R, Yang DT, Gregory K, Sundar H, Deininger M, Radich JP.

J Natl Compr Canc Netw. 2016 Dec;14(12):1505-1512.

PMID:
27956535
48.

Counselees' Perspectives of Genomic Counseling Following Online Receipt of Multiple Actionable Complex Disease and Pharmacogenomic Results: a Qualitative Research Study.

Sweet K, Hovick S, Sturm AC, Schmidlen T, Gordon E, Bernhardt B, Wawak L, Wernke K, McElroy J, Scheinfeldt L, Toland AE, Roberts JS, Christman M.

J Genet Couns. 2017 Aug;26(4):738-751. doi: 10.1007/s10897-016-0044-9. Epub 2016 Dec 5.

49.

Development and Implementation of the Ebola Traveler Monitoring Program and Clinical Outcomes of Monitored Travelers during October - May 2015, Minnesota.

DeVries A, Talley P, Sweet K, Kline S, Stinchfield P, Tosh P, Danila R.

PLoS One. 2016 Dec 1;11(12):e0166797. doi: 10.1371/journal.pone.0166797. eCollection 2016.

50.

NCCN and ELN: What do the guidelines tell us?

Sweet K, Pinilla-Ibarz J.

Best Pract Res Clin Haematol. 2016 Sep;29(3):264-270. doi: 10.1016/j.beha.2016.10.016. Epub 2016 Oct 20. Review.

PMID:
27839567

Supplemental Content

Support Center